How Much Does Rezdiffra (Resmetirom) Cost in Rhode Island in 2026?

Retail and Cash-Pay Pricing Across Rhode Island

The average cash-pay price for brand-name Rezdiffra at Rhode Island retail pharmacies sits at $3,500 per month in 2026, matching the manufacturer list price set by Madrigal Pharmaceuticals. This figure applies to both the 80 mg and 100 mg tablet strengths.

Rhode Island has approximately 130 retail pharmacies, including chains like CVS, Walgreens, and Rite Aid alongside independent community pharmacies. Pricing shows minimal variation across locations because Rezdiffra launched without generic competition and remains under patent protection. The drug received FDA accelerated approval in March 2024 as the first therapy specifically indicated for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced hepatic fibrosis (stages F2-F3) 1. Without insurance or copay assistance, the annual out-of-pocket burden reaches $42,000.

Specialty pharmacies handle most Rezdiffra dispensing in Rhode Island rather than standard retail counters. Patients typically receive the medication through CVS Specialty, Accredo, or AllianceRx Walgreens Prime after completing enrollment paperwork and prior authorization steps. These specialty channels do not discount the drug below list price for uninsured patients, though they often coordinate benefits verification on the patient's behalf.

Rhode Island Medicaid Coverage for Rezdiffra

Rhode Island Medicaid (managed through Neighborhood Health Plan of Rhode Island and UnitedHealthcare Community Plan) covers Rezdiffra with prior authorization. The PA criteria generally require documented evidence of MASH with fibrosis stage F2 or F3 confirmed by liver biopsy or validated noninvasive testing (FibroScan, FIB-4, or ELF score).

Prescribers must typically document that the patient has a BMI of 25 or greater, elevated ALT levels, and has attempted lifestyle modifications for at least 6 months before approval. The PA is usually granted for 12 months with renewal contingent on adherence documentation and evidence of hepatic improvement (declining ALT or stabilized fibrosis scores).

Rhode Island's Medicaid preferred drug list (PDL) places Rezdiffra in a non-preferred tier requiring step therapy documentation. The Endocrine Society's 2023 clinical practice guideline on NAFLD/MASH management supports pharmacotherapy for patients with biopsy-confirmed NASH and fibrosis stage F2 or higher, which aligns with the state's coverage criteria. Copays for Medicaid enrollees who obtain approval are $0 to $3 depending on income tier.

Commercial Insurance Coverage in Rhode Island

Major commercial insurers operating in Rhode Island, including Blue Cross Blue Shield of Rhode Island, UnitedHealthcare, Cigna, and Aetna, have begun adding Rezdiffra to specialty formularies with varying tier placements and access restrictions.

Blue Cross Blue Shield of Rhode Island (BCBSRI), the state's largest commercial insurer with roughly 40% market share, currently places Rezdiffra on Specialty Tier 5. Out-of-pocket costs under BCBSRI plans range from $150 to $500 per month depending on plan design, coinsurance percentage, and whether the member has reached their deductible. Prior authorization requirements mirror those of Medicaid: documented MASH with F2-F3 fibrosis and failed lifestyle intervention.

UnitedHealthcare commercial plans in Rhode Island similarly require PA but may also mandate a specialist referral from a hepatologist or gastroenterologist rather than accepting primary care prescriptions alone. The MAESTRO-NASH trial (N=966) demonstrated that resmetirom 80 mg and 100 mg achieved NASH resolution without worsening fibrosis in 25.9% and 29.9% of patients respectively at 52 weeks, compared with 9.7% for placebo 2. Insurers cite this data when defining their medical necessity criteria.

Patients enrolled in employer-sponsored plans through large Rhode Island employers (CVS Health, Fidelity Investments, Citizens Financial Group) may face different formulary structures, as self-insured employer plans set their own pharmacy benefit terms independently of state insurance mandates.

The Madrigal Pharmaceuticals Savings Card

Madrigal Pharmaceuticals offers a manufacturer copay assistance card that reduces out-of-pocket costs for commercially insured patients. The program covers up to $13,000 in annual copay or coinsurance costs, potentially reducing monthly out-of-pocket to $0 for many Rhode Island patients whose commercial plans cover the drug.

Eligibility requirements include active commercial insurance coverage (not government-funded programs like Medicare, Medicaid, or Tricare), a valid Rezdiffra prescription, and U.S. residency. Rhode Island patients can enroll through the Madrigal support hub website or by calling the manufacturer's patient services line. The card activates at the pharmacy point of sale.

Important limitations exist. The savings card does not apply to patients on Medicare Part D, Medicare Advantage, or Medicaid. It also does not cover the full cost for uninsured patients. The program resets annually on January 1, and Madrigal has not publicly committed to maintaining the $13,000 cap beyond 2026. Dr. Stephen Harrison, medical advisor for Madrigal's clinical program, stated in a 2024 investor presentation: "Patient access is the priority; we designed the copay program to ensure that insurance status is not the barrier to treatment initiation for appropriate MASH patients."

Compounded Resmetirom in Rhode Island: Legality and Access

Compounded resmetirom is available in Rhode Island through licensed 503A compounding pharmacies. Rhode Island Board of Pharmacy regulations permit patient-specific compounding under Section 21-31 of Rhode Island General Laws when a licensed prescriber issues an individualized prescription.

The legal basis rests on the distinction between 503A (patient-specific) and 503B (outsourcing facility) compounding under federal law. Rhode Island accepts 503A compounding for FDA-approved drugs when a prescriber determines a clinical need for a modified formulation, such as a different strength, combination, or dosage form. However, compounding an exact copy of a commercially available drug remains a regulatory gray area that the FDA's guidance documents address on a case-by-case basis.

Pricing for compounded resmetirom varies significantly. Some 503A pharmacies in New England offer compounded versions at substantially lower cost than brand Rezdiffra, though exact pricing requires direct pharmacy consultation. Patients should verify that any compounding pharmacy holds a valid Rhode Island Board of Pharmacy license and follows USP 795 standards for non-sterile compounding.

Clinical considerations matter here. The MAESTRO-NASH trial used manufactured resmetirom tablets with specific bioavailability characteristics 2. Compounded formulations have not undergone the same dissolution and bioequivalence testing. The American Association for the Study of Liver Diseases (AASLD) has not issued specific guidance on compounded thyroid hormone receptor beta agonists, so prescribers accepting this route should monitor liver function tests closely to verify therapeutic response.

Telehealth Prescribing of Rezdiffra in Rhode Island

Rhode Island permits telehealth prescribing of Rezdiffra without geographic restriction within the state. The Rhode Island Department of Health confirmed telehealth parity through regulations updated in 2024, allowing initial consultations and ongoing management for MASH patients via synchronous video or audio-visual platforms.

Prescribers must hold an active Rhode Island medical license or participate in an interstate compact recognized by the state. MASH diagnosis still requires objective documentation (imaging, blood-based biomarkers, or prior biopsy results), but the clinical encounter itself can occur remotely. This matters for patients in rural Washington County or Block Island communities where hepatology specialists are limited.

Telehealth visits for Rezdiffra management typically cost $75 to $200 for initial consultation and $50 to $150 for follow-up visits at direct-pay telehealth practices. Insurance-based telehealth visits carry standard specialist copays. The CDC's 2023 chronic liver disease surveillance data estimates that 25% of U.S. adults have some form of fatty liver disease, suggesting significant unmet demand for accessible hepatology care in smaller states like Rhode Island.

How Rezdiffra Pricing Compares to MASH Management Alternatives

Before Rezdiffra's approval, no FDA-approved pharmacotherapy existed specifically for MASH. Patients relied on off-label options and lifestyle interventions. Understanding this context helps frame the $3,500 monthly cost.

Vitamin E (800 IU daily), recommended by the AASLD practice guidance for non-diabetic NASH patients, costs approximately $15 to $30 per month. Pioglitazone, used off-label for NASH in diabetic patients, runs $10 to $50 per month as a generic. Neither drug demonstrated fibrosis improvement in large trials with the consistency shown by resmetirom.

The MAESTRO-NASH primary endpoints showed resmetirom achieved both NASH resolution (29.9% vs. 9.7% placebo, P<0.001) and fibrosis improvement by at least one stage (25.9% vs. 14.2% placebo) at week 52 2. For patients progressing toward cirrhosis, the cost of liver transplant evaluation and surgery ($400,000 to $800,000) or the lifetime cost of managing decompensated cirrhosis ($50,000+ annually) provides a comparative economic frame.

GLP-1 receptor agonists like semaglutide show promise for MASH (the ESSENCE trial reported positive topline results in 2024), but do not yet carry an FDA indication for liver fibrosis specifically. Their monthly costs ($900 to $1,400 for semaglutide) approach Rezdiffra's tier without the fibrosis-specific approval.

Practical Steps to Minimize Cost in Rhode Island

A systematic approach to cost reduction can lower Rezdiffra expenses from $3,500 per month to under $100 for most insured Rhode Island patients.

Start with benefits verification. Contact your insurer's specialty pharmacy department and request a prior authorization determination before the first fill. Provide FibroScan results (if available), ALT trends over 6+ months, and documentation of lifestyle intervention attempts. The NIH's NASH Clinical Research Network scoring system (NAS score of 4 or higher) strengthens PA applications.

If PA is approved under commercial insurance, immediately enroll in the Madrigal copay card. The combination of insurance coverage plus copay assistance typically reduces monthly cost to $0 to $35.

For Medicaid patients, once PA approval is granted, the drug is dispensed at $0 to $3 per fill. The key barrier is obtaining PA approval. Having a hepatologist submit the authorization (rather than a primary care physician) increases approval rates based on anecdotal reporting from Rhode Island specialty pharmacy networks.

If coverage is denied, file a formal appeal within 30 days. Rhode Island insurance regulations (RIGL 27-18-76) require insurers to provide an external review process for specialty drug denials. Include the MAESTRO-NASH trial data and AASLD guidance supporting treatment of F2-F3 fibrosis patients in your appeal letter.

Monitoring Requirements and Hidden Costs

Rezdiffra treatment involves ongoing laboratory monitoring that adds to total treatment cost. The FDA label recommends baseline and periodic liver function tests (hepatic panel), lipid panels, and thyroid function tests 1.

Most Rhode Island hepatologists order labs at baseline, 12 weeks, 24 weeks, and then every 6 months thereafter. Each lab panel costs $50 to $200 depending on insurance coverage. FibroScan reassessment ($150 to $400 per scan) is typically performed at 12 months to document treatment response for PA renewal.

Resmetirom's mechanism as a thyroid hormone receptor beta-selective agonist means monitoring for thyroid-related effects, though the MAESTRO-NASH safety data showed no clinically significant TSH suppression at therapeutic doses 2. LDL cholesterol reductions of 13% to 16% were observed in trials, which represents a secondary benefit rather than a monitoring concern. The FDA's post-marketing requirement includes a confirmatory outcomes trial (MAESTRO-OUTCOMES) expected to report in 2028.

Rhode Island patients should budget approximately $400 to $800 annually for monitoring-related costs beyond the drug price itself, though most commercial insurance and Medicaid plans cover routine laboratory work at standard copay rates.